RIGVIR LTD

General Information
Registration number: 
40103763354
Year of foundation: 
2014
Industry (NACE 2): 
MANUFACTURING
21 Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.1 Manufacture of basic pharmaceutical products
21.10 Manufacture of basic pharmaceutical products
PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
70 Activities of head offices; management consultancy activities
70.1 Activities of head offices
70.10 Activities of head offices
70.2 Management consultancy activities
70.21 Public relations and communication activities
70.22 Business and other management consultancy activities
Head of the company, position: 
Mr Jurģis Auziņš - Member of the Board
Number of employees: 
11 - 20
Turnover (EUR):
500 001 - 1 000 000
2017
500 001 - 1 000 000
2016
Export volume (EUR):
No data
2017
No data
2016
Export countries: 
Australia
Canada
United Kingdom
United States of America
Certificates: 
RIGVIR is registered in 4 countries (LV;GR;ARM;UZB);
Contact Information
Address: 
Teatra street 9-7, Riga, LV-1050, Latvia
E-mail: 
rigvir [at] rigvir [dot] com
Contact person, position: 
Mrs Kristīne Jučkoviča - CEO
Languages spoken : 
English
Latvian
Russian
Business Profile and Cooperation Interests
Business profile: 

RIGVIR represents group of companies that produce and develop oncolytic virotherapy medicines containing ECHO7 - Live oncolytic and oncotropic virus with immunomodulation activity for cancer treatment. Leading agent - RIGVIR - is approved for treatment of Melan

Cooperation interests: 

We are looking for partner who could facilitate development of our treatment agents both as an collaborative R&D partner or investor in order to successfully commercialise the drug globally.